Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways.

Magistroni V, Mauri M, D'Aliberti D, Mezzatesta C, Crespiatico I, Nava M, Fontana D, Sharma N, Parker W, Schreiber A, Yeung D, Pirola A, Readelli S, Massimino L, Wang P, Khandelwal P, Citterio S, Viltadi M, Bombelli S, Rigolio R, Perego R, Boultwood J, Morotti A, Saglio G, Kim DW, Branford S, Gambacorti-Passerini C, Piazza R.

Haematologica. 2019 Sep;104(9):1789-1797. doi: 10.3324/haematol.2017.179937. Epub 2019 Feb 28.

2.

SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub.

Piazza R, Magistroni V, Redaelli S, Mauri M, Massimino L, Sessa A, Peronaci M, Lalowski M, Soliymani R, Mezzatesta C, Pirola A, Banfi F, Rubio A, Rea D, Stagno F, Usala E, Martino B, Campiotti L, Merli M, Passamonti F, Onida F, Morotti A, Pavesi F, Bregni M, Broccoli V, Baumann M, Gambacorti-Passerini C.

Nat Commun. 2018 Jun 6;9(1):2192. doi: 10.1038/s41467-018-04462-8.

3.

Erratum: OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes.

Piazza R, Ramazzotti D, Spinelli R, Pirola A, De Sano L, Ferrari P, Magistroni V, Cordani N, Sharma N, Gambacorti-Passerini C.

Sci Rep. 2017 May 22;7:46823. doi: 10.1038/srep46823.

4.

OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes.

Piazza R, Ramazzotti D, Spinelli R, Pirola A, De Sano L, Ferrari P, Magistroni V, Cordani N, Sharma N, Gambacorti-Passerini C.

Sci Rep. 2017 Apr 7;7:46290. doi: 10.1038/srep46290. Erratum in: Sci Rep. 2017 May 22;7:46823.

5.

The Novel PIM1 Inhibitor NMS-P645 Reverses PIM1-Dependent Effects on TMPRSS2/ERG Positive Prostate Cancer Cells And Shows Anti-Proliferative Activity in Combination with PI3K Inhibition.

Mologni L, Magistroni V, Casuscelli F, Montemartini M, Gambacorti-Passerini C.

J Cancer. 2017 Jan 1;8(1):140-145. doi: 10.7150/jca.15838. eCollection 2017.

6.

RNA-seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patients.

Piazza R, Cecchetti C, Pirola A, Donandoni C, Fontana D, Mezzatesta C, Magistroni V, Bianchi B, Borin L, Fumagalli M, Gambacorti-Passerini C.

Am J Hematol. 2015 Dec;90(12):E227-8. doi: 10.1002/ajh.24210. Epub 2015 Nov 17. No abstract available.

7.

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene.

Sharma N, Magistroni V, Piazza R, Citterio S, Mezzatesta C, Khandelwal P, Pirola A, Gambacorti-Passerini C.

Mol Cancer. 2015 Jul 16;14:132. doi: 10.1186/s12943-015-0407-0.

8.

ERG deregulation induces IGF-1R expression in prostate cancer cells and affects sensitivity to anti-IGF-1R agents.

Mancarella C, Casanova-Salas I, Calatrava A, Ventura S, Garofalo C, Rubio-Briones J, Magistroni V, Manara MC, López-Guerrero JA, Scotlandi K.

Oncotarget. 2015 Jun 30;6(18):16611-22.

9.

Recurrent ETNK1 mutations in atypical chronic myeloid leukemia.

Gambacorti-Passerini CB, Donadoni C, Parmiani A, Pirola A, Redaelli S, Signore G, Piazza V, Malcovati L, Fontana D, Spinelli R, Magistroni V, Gaipa G, Peronaci M, Morotti A, Panuzzo C, Saglio G, Usala E, Kim DW, Rea D, Zervakis K, Viniou N, Symeonidis A, Becker H, Boultwood J, Campiotti L, Carrabba M, Elli E, Bignell GR, Papaemmanuil E, Campbell PJ, Cazzola M, Piazza R.

Blood. 2015 Jan 15;125(3):499-503. doi: 10.1182/blood-2014-06-579466. Epub 2014 Oct 24.

10.

Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases.

Spinelli R, Pirola A, Redaelli S, Sharma N, Raman H, Valletta S, Magistroni V, Piazza R, Gambacorti-Passerini C.

Mol Genet Genomic Med. 2013 Nov;1(4):246-59. doi: 10.1002/mgg3.23. Epub 2013 Jul 7. Erratum in: Mol Genet Genomic Med. 2014 Mar;2(2):204.

11.

CEQer: a graphical tool for copy number and allelic imbalance detection from whole-exome sequencing data.

Piazza R, Magistroni V, Pirola A, Redaelli S, Spinelli R, Redaelli S, Galbiati M, Valletta S, Giudici G, Cazzaniga G, Gambacorti-Passerini C.

PLoS One. 2013 Oct 4;8(10):e74825. doi: 10.1371/journal.pone.0074825. eCollection 2013.

12.

Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex.

Piazza R, Magistroni V, Mogavero A, Andreoni F, Ambrogio C, Chiarle R, Mologni L, Bachmann PS, Lock RB, Collini P, Pelosi G, Gambacorti-Passerini C.

Neoplasia. 2013 May;15(5):511-22.

13.

Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.

Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A, Antolini L, Mologni L, Donadoni C, Papaemmanuil E, Schnittger S, Kim DW, Boultwood J, Rossi F, Gaipa G, De Martini GP, di Celle PF, Jang HG, Fantin V, Bignell GR, Magistroni V, Haferlach T, Pogliani EM, Campbell PJ, Chase AJ, Tapper WJ, Cross NC, Gambacorti-Passerini C.

Nat Genet. 2013 Jan;45(1):18-24. doi: 10.1038/ng.2495. Epub 2012 Dec 9.

14.

Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.

Redaelli S, Mologni L, Rostagno R, Piazza R, Magistroni V, Ceccon M, Viltadi M, Flynn D, Gambacorti-Passerini C.

Am J Hematol. 2012 Nov;87(11):E125-8. doi: 10.1002/ajh.23338. Epub 2012 Oct 9.

15.

FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery.

Piazza R, Pirola A, Spinelli R, Valletta S, Redaelli S, Magistroni V, Gambacorti-Passerini C.

Nucleic Acids Res. 2012 Sep;40(16):e123. doi: 10.1093/nar/gks394. Epub 2012 May 8.

16.

ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells.

Magistroni V, Mologni L, Sanselicio S, Reid JF, Redaelli S, Piazza R, Viltadi M, Bovo G, Strada G, Grasso M, Gariboldi M, Gambacorti-Passerini C.

PLoS One. 2011;6(11):e28162. doi: 10.1371/journal.pone.0028162. Epub 2011 Nov 30.

17.

Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2.

Mologni L, Dekhil H, Ceccon M, Purgante S, Lan C, Cleris L, Magistroni V, Formelli F, Gambacorti-Passerini CB.

Cancer Res. 2010 Sep 15;70(18):7253-63. doi: 10.1158/0008-5472.CAN-10-1108. Epub 2010 Sep 7.

18.

Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.

Bachmann PS, Piazza RG, Janes ME, Wong NC, Davies C, Mogavero A, Bhadri VA, Szymanska B, Geninson G, Magistroni V, Cazzaniga G, Biondi A, Miranda-Saavedra D, Göttgens B, Saffery R, Craig JM, Marshall GM, Gambacorti-Passerini C, Pimanda JE, Lock RB.

Blood. 2010 Oct 21;116(16):3013-22. doi: 10.1182/blood-2010-05-284968. Epub 2010 Jul 20.

19.

Valproic acid enhances bosutinib cytotoxicity in colon cancer cells.

Mologni L, Cleris L, Magistroni V, Piazza R, Boschelli F, Formelli F, Gambacorti-Passerini C.

Int J Cancer. 2009 Apr 15;124(8):1990-6. doi: 10.1002/ijc.24158.

20.

Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.

Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, Marega M, Gambacorti-Passerini C, Boschelli F.

J Clin Oncol. 2009 Jan 20;27(3):469-71. doi: 10.1200/JCO.2008.19.8853. Epub 2008 Dec 15. No abstract available.

PMID:
19075254
21.

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.

Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, Donella-Deana A, Ahmed S, Redaelli S, Piazza R, Magistroni V, Andreoni F, Scapozza L, Formelli F, Gambacorti-Passerini C.

Cancer Res. 2006 Dec 1;66(23):11314-22. Epub 2006 Nov 17.

22.

The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years.

Piazza RG, Magistroni V, Franceschino A, Andreoni F, Tornaghi L, Colnaghi F, Corneo G, Pogliani EM, Gambacorti-Passerini C.

Blood Cells Mol Dis. 2006 Sep-Oct;37(2):111-5. Epub 2006 Aug 14.

PMID:
16908206
23.

Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients.

Piazza RG, Magistroni V, Andreoni F, Franceschino A, Tornaghi L, Varella-Garcia M, Bungaro S, Colnaghi F, Corneo G, Pogliani EM, Gambacorti-Passerini C.

Leukemia. 2005 Nov;19(11):1985-7. No abstract available.

PMID:
16121215
24.

Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib.

Piazza RG, Magistroni V, Gasser M, Andreoni F, Galietta A, Scapozza L, Gambacorti-Passerini C.

Leukemia. 2005 Jan;19(1):132-4. No abstract available.

PMID:
15510211

Supplemental Content

Loading ...
Support Center